GENOVIS: THE NEW SHARE ISSUE WAS OVERSUBSCRIBED

GENOVIS: THE NEW SHARE ISSUE WAS OVERSUBSCRIBED

Genovis AB (publ) has carried out its earlier published new share issue with
preferential rights to existing shareholders. There has been a high interest and
the new share issue is fully subscribed. 

98 % of the new share issue was subscribed with preferential rights. The rest of
the shares were subscribed without preferential rights within the frame of the
highest amount of the issuing. The issuing ensures Genovis approximately 14 MSEK
after issue expenses. The number of shares increased from 8,708,987 to
10,886,233.
Contract note and notification of allotment of shares subscribed without
subscription rights is estimated to be sent out around the April 14, 2008. 



Find out more, contact:
Sarah Fredriksson, CEO, Genovis AB
Tel: +46 46 10 12 30
sarah.fredriksson@genovis.com



Genovis is a biotechnology company with distinguished core competency in the
fields of nanotechnology and nanoparticles. The company's patented NIMT®
technology (NanoInducedMagneticTransfer) has been developed in order to enable
the life science industry to conduct effective preclinical research. Genovis
shares are listed on the First North, part of OMX Nordic Exchange. Mangold
Fondkommission AB is a Certified Advisor and guarantor of liquidity to the
company.